Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
161 hedge funds and large institutions have $564M invested in Orexigen Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 50 increasing their positions, 51 reducing their positions, and 29 closing their positions.
46% more call options, than puts
Call options by funds: $7.84M | Put options by funds: $5.37M
3% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 29
1% more funds holding
Funds holding: 160 → 161 (+1)
2% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 51
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
33% less capital invested
Capital invested by funds: $843M → $564M (-$278M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$18.2M |
| 2 |
SC
Samlyn Capital
New York
|
+$17.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.4M |
| 5 |
Millennium Management
New York
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$28.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.29M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$8.81M |
| 5 |
SM
Scale Management
Foster City,
California
|
-$7.91M |
OREX Hedge Fund Activity: Q2 2015 in Review
161 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q2 2015, worth a combined $564M — down 33% from $843M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new OREX positions and 29 closed out — a net gain of 1 holder — while 50 added to existing stakes and 51 trimmed.
The largest buyer was Credit Suisse, adding an estimated $18.2M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $28.3M sold.
- 161 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q2 2015, up from 160 in Q1 2015.
- Funds reported $564M of Orexigen Therapeutics, Inc. stock for Q2 2015, down 33% quarter-over-quarter.
- 30 funds opened new Orexigen Therapeutics, Inc. positions in Q2 2015 and 29 closed out, a net change of +1 holder.
- The largest Orexigen Therapeutics, Inc. buyer in Q2 2015 was Credit Suisse, an estimated $18.2M added.
- The largest Orexigen Therapeutics, Inc. seller in Q2 2015 was Capital Research Global Investors, an estimated $28.3M sold.
Based on aggregated 13F filings for Q2 2015.